 Home > Active Ingredient News > Antitumor Therapy > BJU Int: Clinical application of MRI in the diagnosis of prostate cancer before biopsy

BJU Int: Clinical application of MRI in the diagnosis of prostate cancer before biopsy

 Last Update: 2021-09-03
 Source: Internet
 Author: User

Tags

burnt food cancer

prostate supplements consumers report

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the growing aging population, the incidence of prostate cancer remains high
.

It is estimated that by 2040, the incidence of prostate cancer worldwide will nearly double to 2.

Recently, in routine clinical practice
, researchers performed pre-biopsy MRI on men suspected of having prostate cancer but did not have a biopsy, and evaluated the results .

Secondary results included a comparison of transrectal MRI-guided biopsy (TR-MRDB) and transperineal (TP)-MRDB in men with MRI suspicious

In routine clinical practice, researchers performed pre-biopsy MRI on men who were suspected of having prostate cancer but did not have a biopsy, and evaluated the results

Researchers retrospectively evaluated a cohort of men with suspected prostate cancer but no biopsy at two centers.
These men received the second report and data system for prostate imaging in a high-volume center (center 1) between 2015 and 2019.
Version compatible (PI-RADS v2) pre-biopsy MRI examination
.

Those men with suspicious MRI scans underwent TR-MRDB at center 1 and TP-MRDB random biopsy (RB) at center 2

The results include:

1) The total detection rate of grade 1 (GG), GG≥2 and GG≥3 cancers in men with suspected MRI;

2) Avoid biopsy for non-suspicious MRI;

3) Cancer detection rate and biopsy-related complications of TR-MRDB and TP-MRDB
.

In order to reduce the confounding bias of MRDB comparison, the researchers performed inverse probability weighting (IPW) on age, digital rectal examination, prostate specific antigen (PSA), prostate volume, PSA density, and PI-RADS category

Among the 2597 men included, the total detection rates of GG1, GG≥2 and GG≥3 were 8% (210/2597), 27% (697/2597) and 15% (396/2597), respectively
.

57% (1488/2597) of men avoided biopsy

Prostate biopsy comparison

In summary, the MRI results before biopsy can be implemented as a decision-making tool in daily clinical practice
.

Compared with recent trials, it can significantly reduce unnecessary biopsy without affecting the detection of GG≥2/GG≥3

The MRI results before biopsy can be implemented as a decision-making tool in daily clinical practice

Original source:

Bas Israël, Jos Immerzeel, Marloes van der Leest et al.

Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.